Business Description
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | 6.36 | |||||
Interest Coverage | 1.3 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 70.48 | |||||
9-Day RSI | 66.81 | |||||
14-Day RSI | 63.68 | |||||
6-1 Month Momentum % | 7.13 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.2 | |||||
Quick Ratio | 0.92 | |||||
Cash Ratio | 0.26 | |||||
Days Inventory | 226.55 | |||||
Days Sales Outstanding | 150.88 | |||||
Days Payable | 358.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 69.9 | |||||
Operating Margin % | 14.26 | |||||
Net Margin % | 2.12 | |||||
FCF Margin % | -1.9 | |||||
ROE % | 0.62 | |||||
ROA % | 0.37 | |||||
ROIC % | 1.67 | |||||
ROC (Joel Greenblatt) % | 58.36 | |||||
ROCE % | 2.9 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 465.81 | |||||
PE Ratio without NRI | 448.28 | |||||
PS Ratio | 10 | |||||
PB Ratio | 2.9 | |||||
Price-to-Operating-Cash-Flow | 251.9 | |||||
EV-to-EBIT | 76.83 | |||||
EV-to-EBITDA | 53.27 | |||||
EV-to-Revenue | 11.13 | |||||
EV-to-FCF | -587.21 | |||||
Earnings Yield (Greenblatt) % | 1.3 | |||||
FCF Yield % | -0.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Galderma Group AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil CHF) | 1,980.661 | ||
EPS (TTM) (CHF) | 0.179 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 63.68 | ||
14-Day ATR (CHF) | 1.996523 | ||
20-Day SMA (CHF) | 80.7695 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (CHF) | 61.57 - 85.77 | ||
Shares Outstanding (Mil) | 237.57 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Galderma Group AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Galderma Group AG Stock Events
Event | Date | Price(CHF) | ||
---|---|---|---|---|
No Event Data |
Galderma Group AG Frequently Asked Questions
What is Galderma Group AG(CHIX:GALDz)'s stock price today?
When is next earnings date of Galderma Group AG(CHIX:GALDz)?
Does Galderma Group AG(CHIX:GALDz) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |